Welcome to LookChem.com Sign In|Join Free
  • or
Propanoic acid, 2-(2,4-dichlorophenoxy)-2-methyl-, ethyl ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

58937-27-2

Post Buying Request

58937-27-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

58937-27-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 58937-27-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,8,9,3 and 7 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 58937-27:
(7*5)+(6*8)+(5*9)+(4*3)+(3*7)+(2*2)+(1*7)=172
172 % 10 = 2
So 58937-27-2 is a valid CAS Registry Number.

58937-27-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name α-(2,4-dichloro-phenoxy)-isobutyric acid ethyl ester

1.2 Other means of identification

Product number -
Other names ethyl 2-(2,4-dichlorophenoxy)-2-methylpropionate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:58937-27-2 SDS

58937-27-2Relevant academic research and scientific papers

Room temperature C(sp2)-H oxidative chlorination: Via photoredox catalysis

Zhang, Lei,Hu, Xile

, p. 7009 - 7013 (2017/10/05)

Photoredox catalysis has been developed to achieve oxidative C-H chlorination of aromatic compounds using NaCl as the chlorine source and Na2S2O8 as the oxidant. The reactions occur at room temperature and exhibit exclusive selectivity for C(sp2)-H bonds over C(sp3)-H bonds. The method has been used for the chlorination of a diverse set of substrates, including the expedited synthesis of key intermediates to bioactive compounds and a drug.

Synthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS)

Williams, John D.,Torhan, Matthew C.,Neelagiri, Venugopal R.,Brown, Carson,Bowlin, Nicholas O.,Di, Ming,McCarthy, Courtney T.,Aiello, Daniel,Peet, Norton P.,Bowlin, Terry L.,Moir, Donald T.

, p. 1027 - 1043 (2015/03/04)

The increasing prevalence of drug-resistant bacterial infections is driving the discovery and development not only of new antibiotics, but also of inhibitors of virulence factors that are crucial for in vivo pathogenicity. One such virulence factor is the type III secretion system (T3SS), which plays a critical role in the establishment and dissemination of Pseudomonas aeruginosa infections. We have recently described the discovery and characterization of a series of inhibitors of P. aeruginosa T3SS based on a phenoxyacetamide scaffold. To better characterize the factors involved in potent T3SS inhibition, we have conducted a systematic exploration of this structure, revealing several highly responsive structure-activity relationships indicative of interaction with a specific target. Most of the structural features contributing to potency were additive, and combination of those features produced optimized inhibitors with IC50 values 1 μM.

SPIROIMIDAZOLONE DERIVATIVE

-

Page/Page column 170; 171, (2012/04/10)

The present invention relates to a compound represented by the following formula (1): wherein W, X, Y, R1, R2, R33, R34, m and n are as defined in the claims, or a pharmacologically acceptable salt thereof.

INHIBITORS OF BACTERIAL TYPE III SECRETION SYSTEM

-

Page/Page column 60-61; 63, (2010/11/03)

Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 58937-27-2